| Replication or exploration? Sequential design for stochastic simulation experiments M Binois, J Huang, RB Gramacy, M Ludkovski Technometrics 61 (1), 7-23, 2019 | 142 | 2019 |
| Analyzing stochastic computer models: A review with opportunities E Baker, P Barbillon, A Fadikar, RB Gramacy, R Herbei, D Higdon, ... Statistical Science 37 (1), 64-89, 2022 | 57* | 2022 |
| Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after≥ 2 prior therapies: 3-year follow-up … SJ Schuster, LH Sehn, NL Bartlett, M Matasar, S Assouline, P Giri, ... Blood 142, 603, 2023 | 19 | 2023 |
| On‐site surrogates for large‐scale calibration J Huang, RB Gramacy, M Binois, M Libraschi Applied Stochastic Models in Business and Industry 36 (2), 283-304, 2020 | 16 | 2020 |
| Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B‐cell malignancies intolerant to ibrutinib and/or acalabrutinib M Shadman, JP Sharman, MY Levy, R Porter, SF Zafar, JM Burke, ... Hematological Oncology 39, 2021 | 10 | 2021 |
| Mosunetuzumab monotherapy demonstrates activity and a manageable safety profile in patients with relapsed or refractory Richter's transformation CY Cheah, S Assouline, R Baker, NL Bartlett, D El-Sharkawi, P Giri, M Ku, ... Blood 142, 614, 2023 | 9 | 2023 |
| NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma RT Hoppe, RH Advani, WZ Ai, RF Ambinder, P Aoun, CM Bello, ... J Natl Compr Canc Netw 12 (2), 2014 | 7 | 2014 |
| Multi-output calibration of a honeycomb seal via on-site surrogates J Huang, RB Gramacy Technometrics 64 (4), 548-563, 2022 | 4 | 2022 |
| CAMMA 1: a multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple … R Vij, H Schade, S Trudel, AC Chang, J Huang, D Samineni, T Sumiyoshi, ... J. Clin. Oncol 40, 16, 2022 | 4 | 2022 |
| A frequentist approach to dynamic borrowing R Li, R Lin, J Huang, L Tian, J Zhu Biometrical Journal 65 (7), 2100406, 2023 | 3 | 2023 |
| PB1890: zanubrutinib in acalabrutinib-intolerant patients (PTS) with B-cell malignancies M Shadman, IW Flinn, EC Kingsley, B Freeman, MY Levy, J Cultrera, ... HemaSphere 6, 1769-1770, 2022 | 1 | 2022 |
| PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY … R Vij, H Schade, S Trudel, AC Chang, J Huang, D Samineni, T Sumiyoshi, ... HemaSphere 6, 1905-1906, 2022 | 1 | 2022 |
| CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory … S Delimpasi, H Quach, M Cavo, PJ Ho, C Lee, A Santoro, R Schots, ... J. Clin. Oncol 40, 16, 2022 | 1 | 2022 |
| Sequential learning, large-scale calibration, and uncertainty quantification J Huang Virginia Tech, 2019 | 1 | 2019 |
| Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After≥ 2 Prior Therapies: 3-Year Follow-Up … SJ Schuster, LH Sehn, NL Bartlett, M Matasar, S Assouline, P Giri, ... Presented at the 12th Annual Meeting of the Society of Hematologic Oncology …, 2024 | | 2024 |
| IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After≥ 2 Prior Therapies: 3-Year … SJ Schuster, LH Sehn, NL Bartlett, M Matasar, S Assouline, P Giri, ... Clinical Lymphoma Myeloma and Leukemia 24, S497, 2024 | | 2024 |
| P-019 Novel combination immunotherapy for relapsed/refractory multiple myeloma (RRMM): initial Phase 1 safety run-in results for cevostamab in combination with pomalidomide and … T Jelinek, A Spencer, A Krishnan, S Trudel, S Harrison, M Breuleux, ... Clinical Lymphoma Myeloma and Leukemia 23, S43, 2023 | | 2023 |
| Bayesian Analysis of Rank Data with Covariates and Heterogeneous Rankers...................................................... Xinran Li, Dingdong Yi and Jun S. Liu 1 The … M Oesting, K Strokorb, P Barbillon, A Fadikar, RB Gramacy, R Herbei, ... Statistical Science [ISSN 0883-4237 (print); ISSN 2168-8745 (online)] 37 (1), 2022 | | 2022 |
| S867 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS R Advani, N Bartlett, S Smith, M Roschewski, L Popplewell, I Flinn, ... HemaSphere 3, 388, 2019 | | 2019 |
| DECONSTRUCTIVE ANALYSIS OF DIGITAL PATHOLOGY INFERENCES US Patent App. No. 63/394,934, 0 | | |
Robert B. GramacyVirginia TechVerified email at vt.edu
